#biobank

[cbirt]

Centuries after the first proteins were identified and characterized, their complexity proves a challenge for scientists all over the world. Their creation, evolution, and many variations are questions for which we have only just begun to uncover the answers. A new bioinformatics tool has now been developed that can provide researchers with a way to analyze data and map protein sequences and structures on a large scale. This has important implications for protein modeling and sequencing technologies.

Genomes provide the template on which all life is created and maintained. Despite the high accuracy of DNA replication mechanisms found in living organisms, certain mutations can still occur and be passed on. Such mutations can change the function and structure of the protein that the gene is supposed to encode. Nearly all Mendelian diseases are caused by variations in the proteome.

In lieu of the time-consuming and exhaustive process of determining protein structures and mutations in the lab, researchers have now turned to bioinformatics as an alternative method to quickly and cheaply generate highly accurate and precise protein structure models. Many protein modeling tools have been developed to predict mutations and their impact with as much accuracy and precision as possible. The majority of such tools use only protein sequencing information from both the protein as well as its variants in order to produce results. While such a method is advantageous in that it is applicable to nearly all genetic mutations, they don’t account for the structure of the mutated variants, resulting in a loss of valuable information that can be garnered from taking the proteins’ 3-dimensional structures into account. This is especially important as it allows for distinguishing between mere correlations in mutation occurrence and causative variations. Hence, the results obtained through such methods may not be as accurate or precise.

Continue Reading

[rayhaber]

Covid-19'un Kalp Sağlığı Üzerindeki Uzun Süreli Etkileri

Amerika Birleşik Devletleri’ndeki bilim insanları, Covid-19’a yakalanan bireylerin, hastalığı geçirenlerin sonraki üç yıl içinde kalp krizi, felç ve ölüm riski açısından, hastalığı hiç geçirmeyenlere göre iki kat daha fazla risk taşıdığına dair önemli bulgular elde etti. Bu araştırma, Atherosclerosis, Thrombosis, and Vascular Biology dergisinde yayımlandı. Çalışma, Güney California Üniversitesi,…

[scientificinquirer-blog]

DAILY DOSE: September was hottest month around the world ever recorded; China plans on doubling size of space station, challenging NASA.

HOT HOT HEAT (AGAIN). September 2023 recorded the highest global temperatures ever, surpassing previous records for July and August. This unprecedented surge in temperature shocked scientists. September was 1.8C warmer than pre-industrial levels, with a leap of 0.5C from the previous record for the month – the most significant temperature jump ever. European and Japanese data confirmed these…

[thepastisalreadywritten]

By Sharon Guynup | 21 January 2023

On the screen and on the street, strawberry blonds and those with auburn tresses attract attention, and always have.

That is, in part, because red hair is an exotic trait, occurring in just one or two out of every 100 people.

While the gene variants that endow flaming locks are rare, redheads are not destined to vanish from the population, despite recurring claims to that effect.

“Redheads are not going extinct,” says Katerina Zorina-Lichtenwalter, a postdoctoral fellow at the Institute for Behavioral Genetics at University of Colorado, Boulder.

To understand why this is so, it’s necessary first to understand why there are redheads in the first place.

As it turns out, it’s not only tabloids that are interested in flame-haired people. Scientists are too.

There’s more research on the variations in human hair color than you might expect, and the science makes it clear that crimson locks are not becoming increasingly rare, nor will they disappear any time soon. It’s a trait that dates to prehistory.

Analysis of 50,000-year-old DNA revealed that some Neanderthals were pale-complected redheads.

A famous 3,800-year-old Bronze Age mummy, known as the Beauty of Loulan, was unearthed from a desert cemetery in northwestern China with intact sepia-colored hair.

From the fifth century on, in what is now southeast Europe and Turkey, the mythological King Rhesus of the ancient Thracians was depicted on Greek pottery with carrot-colored hair and beard.

The gene variants involved are recessive, meaning two copies—one from the mother and one from the father—are required to produce a red-haired child.

"Only if both parents are redheads can they be almost certain their baby will have fiery hair," Zorina-Lichtenwalter says.

In her book Red: A History of the Redhead, author Jacky Colliss Harvey characterizes the odds of having a crimson-haired baby this way:

“In the great genetic card game, red hair is the two of clubs. It is trumped by every other card in the pack.”

The genetics of red

Ginger coloring in people—as well as horses, dogs, pigs, and other mammals—is conferred by just a handful of genetic mutations that both parents must carry.

The “redhead gene” was discovered in 1995 by a team including Ian Jackson, now a professor emeritus at Scotland’s University of Edinburgh.

This melanocortin 1 receptor gene, or MC1R, plays a key role in producing melanin, the tan pigment that protects skin from ultraviolet radiation (sunlight) and also colors eyes and skin.

One type, eumelanin, endows brown or black hair.

Pheomelanin creates red or blonde locks and confers light skin and freckles.

In people who have red hair, the skin cells (melanocytes) that produce pigment have a variant receptor on the cell surface.

When exposed to UV light, this variant fails to trigger a switch that changes melanin pigment from yellow/red to the protective brown/black.

“MC1R is one of several genes that work together to produce dark melanin, and without that switch, you’re going to have light skin,” says Zorina-Lichtenwalter—and easily burn when out in the sun.

In their 1995 research, Jackson and his colleagues compared 30 Irish and British redheads with the same number of brunettes.

More than 80 percent of rosy-haired and/or fair-skinned people carried variations in the MC1R gene; but just 20 percent of the brown-haired individuals did.

When they published the study, geneticist Richard Spritz told the media “this is the first time in humans that a specific gene for any common visible characteristic has been identified.”

Genetic advantage—and peril

Pale coloration bestowed a key advantage to cultures migrating from sunnier regions into northern Europe with its gray skies and short winter days.

“There was evolutionary pressure to lose skin pigmentation,” Zorina-Lichtenwalter explains, because lighter skin absorbs more UV, which produces more vitamin D from the limited amount of sunlight in northern regions.

Vitamin D helps the body absorb and retain calcium, build stronger bones, and protect against inflammation.

These health benefits increased the likelihood that women would survive pregnancy and birth, successfully passing on genes for light skin and red or blonde hair to their offspring.

The trait flourished in the United Kingdom and Ireland, where there are, by far, more fair-skinned redheads than anywhere else on Earth.

Some unofficial estimates peg the number at around 10 percent.

Much of the research into redhead genetics stems from their elevated skin cancer risk.

The MC1R gene mutations linked to crimson hair, light skin, and freckles also allows more UV to reach DNA and damage it.

One study found that people carrying a so-called R variant of the MC1R gene had a 42 percent higher incidence of melanoma, one of the most aggressive forms of cancer.

Melanoma is 20 times more prevalent in Caucasians than in African Americans.

However, the average age for melanoma diagnosis is 65. Therefore, Zorina-Lichtenwalter says, “it doesn’t threaten reproductive fitness.”

At that age, women have already passed their genes to the next generation. This is why, she says, redheads are unlikely to disappear from the gene pool.

More ginger genes

When he was working on that 1995 genetic analysis, Jackson knew there was more to understand about the factors conferring red hair.

“It seemed logical that there were other genes involved,” he says, but deeper exploration was not yet possible: Genetic research was extremely slow and costly.

While rapid advances in genetic technologies and computing had launched the Human Genome Project, the first draft of the genetic map would not be complete until 2001.

Now, a quarter-century later, quick, inexpensive genetic research is the norm.

Jackson and his colleagues recently revisited their inquiry with resources unthinkable in 1995.

They analyzed DNA from the UK Biobank, which contains genetic and health information on a half million residents of the United Kingdom.

They discovered eight previously unknown genetic variants that affect red hair and skin pigmentation.

“To go through and find those genes using the Biobank was very, very satisfying,” Jackson says.

This research, published in 2022, identified most of the genetic variation contributing to differences in hair color.

Most redheads have two MC1R variants, according to Jackson, one from each parent. But several other genes also affect whether your hair will be red.

“It's a particular combination that gives rise to red hair,” he says.

Researchers assigned each of the implicated genes a “genetic risk score”: with some variants exerting higher probability of red locks.

Others had much less clout but were still associated. You don’t need all of them to have red hair, Jackson says.

“MC1R is king when it comes to red headedness,” Zorina-Lichtenwalter says.

“It has a tremendous amount of say in whether we'll have dark pigmentation or light pigmentation.”

More than four-fifths of redheads carry MC1R; whereas the remaining reds are caused by other genes.

Geography and ancestry

A recent U.K. genetic study correlated the incidence of burnished tresses with place of birth, with more redheads in the country’s north and west.

“In the Biobank, you've got the latitude and longitude of birthplace of every individual,” Jackson says.

“The further north you were born, the higher the likelihood of having red hair.”

Red-haired, light-skinned genetics thrived in remote regions, closed communities, and islands––such as Scotland (estimates of redheads there range from Jackson’s 6 percent up to 12 or 14 percent); Ireland (10 percent); and Britain (6 percent).

While the populations of these countries are no longer cut off from the rest of the world, “when you have an insular population, isolated from others reproductively, then whatever alleles, they rise in frequency from generation to generation,” Zorina-Lichtenwalter says.

However, redheads are not only Celts or Caucasians. Their distribution is a testament to the global movement of DNA across societies and landscapes.

Although most common in Northern Europe, parts of Russia, and among European descendants in Australia, there are redheads from all ethnicities and races.

For example, both Morocco and Jamaica have higher-than-average numbers.

The reason, Zorina-Lichtenwalter says, is that several genes are responsible for triggering dark eumelanin production to protect skin.

But for hair color, she says “MC1R does appear to dominate, which is why variants in MC1R can still produce red hair in Jamaicans and other dark-skinned people.”

We are not amidst a redhead extinction event

"Claims that redheads are a dying breed are not new, and some of them were clearly linked to financial gain," Jackson says.

One headline that started an uproar blared, “Redheads May Soon Join Polar Bears As Casualties Of Climate Change,” which is a serious stretch.

"Climate change is creating more extreme temperature, drought, and flood; but the possibility that it will impact UV radiation enough to alter Northern Hemisphere genetics––within the predicted few hundred years––is slim," says Zorina-Lichtenwalter.

The source of this claim was Alistair Moffat, CEO of the now-defunct genetic testing company ScotlandsDNA.

Prior to that, the Oxford Hair Foundation (also dissolved) predicted that redheads would be extinct by 2100, with the gene variant that confers flaming hair slowly disappearing.

“[The institute] was a front, funded by a hair dye and cosmetics company to generate interest in hair color,” Jackson says.

While recessive genes can become rare, they don't utterly disappear unless every person who carries that gene either perishes—or does not bear children.

And clearly that’s not going to happen.

Wherever they live, redheads garner outsized attention, sometimes stigmatized, sometimes admired.

As testament to their continued presence in the world, they celebrate themselves in yearly “red pride” events in the U.K., France, and Italy, as well as the U.S.

The largest may be an event in August, when thousands of gingers from across the world convene in the Netherlands for “Redhead Days.”

[cro-services]

Healthcare Innovation in Global Solutions at Clinfinite Solution

Introduction

In today’s fast-paced healthcare industry, organizations must adapt to global trends and provide solutions that cater to a wide range of markets. Clinfinite Solution, with its strong international presence, offers global solutions that support pharmaceutical companies, biotechnology firms, and healthcare providers in successfully navigating the complexities of clinical research. With expertise in regulatory compliance, patient recruitment, data management, and trial monitoring, Clinfinite Solution is the partner of choice for a global approach to healthcare innovation.

Bringing Global Expertise to Clinical Trials

At Clinfinite Solution, we understand the challenges that come with conducting clinical trials across multiple countries and regions. Our global solution approach combines our deep local knowledge with international expertise, ensuring that every trial adheres to the highest standards of quality and regulatory compliance. Whether your clinical trial spans across the U.S., Europe, Asia, or beyond, we provide seamless coordination to help you navigate the varied regulatory environments and logistical complexities involved. Our global expertise enables us to deliver timely results and accelerate the approval process.

Wide-Ranging Patient Recruitment Strategies

One of the critical components of successful global clinical trials is recruiting and retaining patients across different regions. Clinfinite Solution excels in designing and implementing patient recruitment strategies tailored to each country and population. Our extensive network of patient databases, digital outreach tools, and partnerships with healthcare providers worldwide allow us to effectively target the right participants for clinical studies. By focusing on patient-centric solutions, we ensure that enrollment is timely, diverse, and adheres to the highest ethical standards.

Seamless Data Management Across Borders

Handling data from clinical trials conducted in multiple regions presents its own set of challenges, particularly regarding data integrity and compliance with various data protection regulations. At Clinfinite Solution, we use advanced data management systems and technologies to ensure the secure, efficient, and compliant management of clinical trial data. Our team ensures that data is collected, processed, and stored in accordance with international standards like GDPR in Europe and HIPAA in the United States. We make it easy for stakeholders to access real-time, accurate data, no matter where the trial is taking place.

Regulatory Support for Global Compliance

Navigating the regulatory landscape is a significant challenge for pharmaceutical and biotech companies looking to launch new products globally. At Clinfinite Solution, we offer regulatory services that provide strategic advice and hands-on support throughout the clinical trial process. Our regulatory affairs experts are well-versed in the requirements of major regulatory bodies like the FDA (USA), EMA (Europe), and ICH (International Conference on Harmonisation), among others. We ensure that every step of your clinical trial adheres to the regulatory standards required in each country, helping to speed up the approval process and minimize delays.

Multinational Site Management and Monitoring

Managing clinical trial sites in multiple countries requires careful coordination and consistent oversight. Clinfinite Solution’s site management team ensures that all sites are compliant with local regulations, operating efficiently, and adhering to clinical trial protocols. Our team of Clinical Research Associates (CRAs) and site monitors oversee site activities, ensure the integrity of collected data, and address any issues that may arise during the trial. This global solution site management service helps streamline the process and ensures that trials run smoothly and on schedule.

Global Medical Writing Services

Effective and compliant documentation is a fundamental part of any clinical trial, especially when conducting multinational studies. Clinfinite Solution offers comprehensive medical writing services that produce clear, concise, and accurate study protocols, clinical study reports, and regulatory submissions. Our global team of medical writers is proficient in preparing documents for various regulatory agencies, ensuring that they meet the requirements of different regions and authorities. We simplify the process of creating international documentation that is both comprehensive and compliant.

Pharmacovigilance and Safety Monitoring

Ensuring patient safety is paramount, particularly in global trials involving diverse patient populations. Clinfinite Solution provides robust pharmacovigilance services to monitor the safety of the product being tested. We track and report adverse events, providing timely safety assessments to regulatory authorities across the globe. Our global pharmacovigilance team ensures compliance with local and international reporting requirements, offering real-time data analysis and risk mitigation strategies.

Conclusion: A True Global Partner in Clinical Research

Clinfinite Solution’s global approach to clinical trials ensures that your projects are managed with the utmost efficiency and expertise. From patient recruitment to regulatory compliance, and data management to site monitoring, our global solutions are designed to meet the demands of international clinical research. With a commitment to excellence, Clinfinite Solution is the partner you can trust to navigate the complexities of global healthcare innovation. Whether you're running a trial in one country or multiple, we provide the support and expertise to help bring your products to market faster and more efficiently.

[todayworldnews2k21]

India sets up its first diabetes biobank

A person receives blood sugar test. File | Photo Credit: Reuters Aimed at facilitating advanced research on diabetes, the variations of the Indian type and other related disorders, the Indian Council of Medical Research (ICMR) in collaboration with the Madras Diabetes Research Foundation (MDRF) has set up the country’s first diabetes biobank. This repository of population-based biological…

[nando161mando]

"Race science group say they accessed sensitive UK health data" https://theguardian.com/world/2024/oct/17/race-science-group-say-they-accessed-sensitive-uk-health-data

In 'Resisting AI' I specifically warned about UK Biobank, genome-wide association studies and the emergence of AI-driven eugenics.

[billloguidice]

Caffeine consumption associated with lower risk of developing CM - New Study

Caffeine consumption associated with lower risk of developing CM - New Study #caffeine #coffee #tea #plasmametabolites #cm #research #newstudy #newresearch

In a new study published in The Journal of Clinical Endocrinology & Metabolism (JCEM) from Oxford Academic, “Habitual Coffee, Tea, and Caffeine Consumption, Circulating Metabolites, and the Risk of Cardiometabolic Multimorbidity,” consumers of moderate amounts of caffeine had the lowest risk for Cardiometabolic Multimorbidity (CM). CM is one of the most common and harmful multimorbidity profiles…

[thetanningguru]

Shedding New Light on UV Exposure: Sunbed Health Benefits Finally Revealed

For years, we’ve been warned about the dangers of ultraviolet (UV) light exposure, particularly from sunbeds. However, a groundbreaking new study from researchers at the University of Edinburgh suggests that UV exposure may have more health benefits than previously thought, especially in countries with low sunlight like the United Kingdom. The Study at a Glance Published in the journal Health &…

[cbirt]

OpenAI’s ChatGPT: A Promising AI Tool for Early Detection of Alzheimer’s Disease

Researchers at Drexel University’s School of Biomedical Engineering, Science, and Health Systems have found that ChatGPT, an AI-powered chatbot program, may be able to detect early signs of Alzheimer’s disease. In a study, the program analyzed conversations between individuals with Alzheimer’s disease and healthy controls and was able to accurately identify those with the disease with an accuracy rate of 80%. ChatGPT uses AI algorithms to generate responses similar to how a human would respond to user input and be able to detect differences in language patterns, such as difficulty finding the right words and repetitive language, in individuals with Alzheimer’s disease. While more research is needed, the study suggests that OpenAI’s GPT-3 could potentially be used as a non-invasive, cost-effective method for detecting Alzheimer’s disease in its early stages. 

Continue Reading

[healthcaremarketanalysis]

Global Biobanking Market Worth $5.0 billion by 2028

The global biobanking market, valued at $2.9 billion in 2023, is projected to reach $5.0 billion by 2028, growing at a CAGR of 11.4%. The market's growth is driven by increasing investments and funding for biobanks, a focus on genetic testing and precision medicine, the preservation of cord blood stem cells, and favorable funding for regenerative medicine research. Challenges include the high cost of automated equipment and biospecimen sample management issues. Emerging markets such as China, India, and South Korea offer significant growth opportunities due to lower manufacturing costs and skilled resources. Key players in the market include Thermo Fisher Scientific, PHC Holdings Corporation, Becton, Dickinson and Company, QIAGEN, and Merck KGaA. The equipment segment held the largest market share in 2022, with the Asia Pacific region expected to register the highest CAGR during the forecast period.

Download PDF Brochure:

Biobanking Market Dynamics

DRIVER: Growing investments and funding for biobanks

Biobanks have gained significant recognition from governments, research organizations, and funding agencies worldwide, resulting in a rise in investments in biobanks. For example, the Biorepository and Precision Medicine Initiative (PMI) Cohort Program, funded by the US National Institutes of Health (NIH), aims to collect biological samples from one million or more individuals to create a national research resource. Similarly, the European Commission has invested in the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI), a pan-European infrastructure for biobanking and biomolecular resources.

RESTRAINT: High cost of automated equipment

The high cost of automated equipment is expected to restrain the growth of the market. Automated equipment, such as advanced sample handling systems, can significantly improve the efficiency and quality of biobanking operations. However, the high cost of this equipment can be a significant barrier to the entry of smaller biobanking companies or those with limited financial resources. For instance, the cost of an automated storage system can vary depending on the size and complexity of the system. The initial investment in an automated storage system can be significant, with costs ranging from tens of thousands to hundreds of thousands of dollars. In addition to the initial investment, there are ongoing maintenance and operational costs that must be considered, such as software updates, repairs, and training.

OPPORTUNITY: Emerging countries to provide lucrative opportunities

Developing countries are expected to offer significant growth opportunities for players operating in the global market due to the low-cost manufacturing advantage offered by these countries, coupled with the availability of skilled resources at lower costs. Moreover, as compared to developed markets, such as the US, Germany, and Japan, the demand for medical products in emerging Asian markets, such as China and India, is growing at a robust rate. This has prompted medical product companies to focus on these countries for future growth.

CHALLENGE: High operational cost of biobanks

Due to the increasing utilization of biospecimens for research and the emergence of new technologies, there is a growing focus on the availability and quality of biospecimens and their effective collection. However, the long-term economic situation of biobanks is still mostly unclear, which raises questions regarding their overall sustainability. Several costs add up in the complete functioning of a biobank, including in-case collection, tissue processing, storage management, sample distribution, and infrastructure and administration costs. Additionally, high investments are required to set up the required infrastructure in biobanks. For instance, the cost of installing laboratory facility infrastructure, liquid nitrogen supplies, mechanical freezers, and software systems add to the overall operating costs. Since biobanks have to store samples over a period of time, there is a significant need to optimize operations and costs for their long-term sustainability

Request 10% Customization

The equipment segment dominated biobanking market by product & service:

The equipment segment held the largest share of the global market in 2022. This is primarily attributed to the increasing number of biobanks and biosamples, due to which the demand for equipment remains high. The biobanking equipment segment encompasses a range of specialized products essential for the processing, analysis, storage, and transport of biological samples. These specimens may include human tissues, cells, blood, DNA, and other biospecimens collected from patients, donors, or research participants. The segment covers a broad spectrum of solutions and technologies catering to the diverse needs of biobanks, research institutes, and medical facilities.

The North America region catered the largest share of the biobanking market in 2022.

The biobanking market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory. This can be attributed to the increasing number of biobanks and the growing investments in biobanking infrastructure. Major healthcare institutes and research organizations in North America have made substantial commitments to expanding their biobanking capabilities. Additionally, the rising prevalence of chronic diseases and the subsequent demand for personalized medicine has fueled the growth of the biobanking market in North America, with biobanks playing a pivotal role in storing and providing high-quality biological specimens for research and development purposes.

Key players in the biobanking market include Thermo Fisher Scientific, Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (US), QIAGEN N.V. (Germany), Merck KGaA (Germany), Avantor, Inc. (US), Cryoport, Inc. (US), Tecan Trading AG (Switzerland), Azenta, Inc. (US), Greiner Holding AG (Austria), Hamilton Company (US), Micronic (Netherlands), AMSBIO (UK), Bay Biosciences LLC (US), BioKryo (Germany), SPT Labtech (UK), ASKION GmbH (Germany), Cell&Co BioServices (France), Ziath Ltd. (UK), CTIBiotech (France), Cureline (US), Firalis Group (France), Sopachem (Netherlands), ProteoGenex (US), and US Biolab Corporation, Inc. (US).

Recent Developments

In February 2023, PHC Corporation of North America launched the PHCbi Brand VIP ECO SMART Ultra-low Temperature Freezer with industry-leading energy efficiency.

In September 2022, Cryoport entered into a strategic partnership with BioLife Plasma Services to offer supply chain solutions and service offerings, such as bioservices and cryo-processing, for BioLife Plasma Services.

Biobanking market - Report Highlights:

The market size is updated for the base year 2022 and forecasted from 2023 to 2028 by studying the impact of the recession on the overall biobanking industry.

The new edition includes the impact of the recession on the biobanking market (especially the region-wise impact in the geographic analysis section) in 2022. There is a variation in the growth rate of the market due to the ongoing recession.

Additional points such as ranges/scenarios, trends/disruptions impacting customers' businesses, pricing analysis, value chain analysis, supply chain analysis, ecosystem analysis, patent analysis, key conferences and events (2022-2023), list of key regulatory bodies, regulatory landscape, Porter's Five Forces analysis, key stakeholders, the influence of stakeholders on buying decisions, and buying criteria among end users have been added in the market overview chapter.

The new edition of the report provides updated financial information till 2022 (depending on availability) for each listed company in a graphical representation. This will help in the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating region/country, and business segment focus in terms of the highest revenue-generating segment.

Recent developments help us to understand market trends and the growth strategies adopted by players in the market.

Tracking the portfolios of prominent market players helps analyze the major products in the biobanking market. The new edition of the report provides an updated product portfolio of the companies profiled in the report.

Key market strategies/right to win, market share analysis for 2022, revenue share analysis of key market players from 2020 to 2022, and competitive leadership mapping have been added in the competitive landscape section of the report.

The new version of the report includes competitive leadership mapping for companies operating in the market. This new section is an output of a comprehensive study of the key vendors offering biobanking products. The top 25 vendors were shortlisted from a list of 50+ vendors, and these were evaluated based on market share/ranking and product footprint, rated and positioned on a 2x2 quadrant, referred to as Company Evaluation Quadrant, categorizing them as Stars, Emerging Leaders, Pervasive Players, and Participants.

The new version of the report includes the startup/SME evaluation quadrant for 10 companies operating in the biobanking market. This updated section is an output of a comprehensive study of the key startup vendors offering biobanking products. The top 10 vendors were shortlisted from a list of 50+ vendors, and these vendors were evaluated based on their product portfolio and business strategy, rated and positioned on a 2x2 quadrant, referred to as Competitive Leadership Quadrant, categorizing them as Progressive Companies, Starting Blocks, Responsive Companies, and Dynamic Companies.

In the new edition of the report, the Rest of the World is segmented into Latin America and the Middle East and Africa. Country-level markets for Brazil and the Rest of Latin America in the Latin American region have been added.

The new version of the report includes the ownership segment, which is further segmented into national/regional agencies, non-profit organizations, universities, and private organizations.

The new version of the report includes an end-user segment, which is further segmented into pharmaceutical & biotechnology companies and CROs, academic and research institutes, and hospitals.

[allmarketnews]

Biobanking Market Future Aspect Analysis and Current Trends by 2024 to 2034

The Biobanking Market is crucial to the advancement of biomedical and translational research because it facilitates the collection and preservation of biological samples, including blood, tissues, and nucleic acids, which are then made available for use in studies aimed at identifying disease-relevant biomarkers. These biomarkers can then be utilized for diagnosis, prognosis, and drug response prediction. A key factor propelling the market is the increase in the quantity of research projects in this sector. These segment’s research efforts are supported by government funding available for stem cell therapies, regenerative medicine, and cell and gene therapy. Aside from this, the growing popularity of cord blood banking will support the expansion of this industry.

The Biobanking market is predicted to develop at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2034, when it is projected to reach USD 184.28 Billion, based on an average growth pattern. The market is estimated to reach a value of USD 81.50 Billion in 2024.

Know More About Biobanking Market, Download Sample Report: https://wemarketresearch.com/reports/request-free-sample-pdf/biobanking-market/1124

Biobanking refers to the organized collection and maintenance of biological specimens and their associated data. These banks store a variety of samples, such as human tissues, blood, DNA, and other biological materials, along with crucial information about the donors, including their medical history, lifestyle, and genetic data. This systematic storage allows researchers to access high-quality, well-documented specimens for their studies.

Key Market Players

The Biobanking Market is dominated by a few large companies, such as

Thermo Fisher Scientific Inc.

PHC Holdings Corporation

Becton, Dickinson and Company

QIAGEN N.V.

Merck KGaA

Sampled

Avantor, Inc.

Cryoport, Inc.

Tecan Trading AG

Azenta, Inc.

Greiner Holding AG

Others

Global Biobanking Market- Segmental Analysis

By Sample Type

Human Tissues

Stem Cells

Other Biological Samples

By Application

Therapeutics

Research

Clinical Trials

By Storage Type

Manual Storage Systems

Automated Storage Systems

By End User

Pharmaceutical and Biotechnology Companies

Academic Research Institutes

Hospitals and Diagnostic Laboratories

Purchase a Copy of this Biobanking Market research report at@ https://wemarketresearch.com/purchase/biobanking-market/1124?license=single

Challenges in Biobanking

Standardization: Developing standardized procedures for sample collection, processing, and storage is essential to ensure the quality and comparability of specimens across different biobanks.

Funding and Sustainability: Maintaining biobanks requires significant financial resources. Securing long-term funding and demonstrating the value of biobanks to stakeholders are ongoing challenges.

Technological Advances: Rapid advancements in technology, such as genomics and data analytics, require biobanks to continually update their infrastructure and capabilities.

Interoperability: Facilitating data sharing and collaboration between biobanks, both nationally and internationally, is crucial for maximizing the potential of biobanked samples.

The Future of Biobanking

The future of biobanking is bright, with several promising trends and developments:

Integration with Digital Health: The integration of biobanks with digital health technologies, such as electronic health records (EHRs) and wearable devices, can provide more comprehensive data and enhance research capabilities.

Global Collaboration: Increasing international collaboration and data sharing among biobanks will help address global health challenges and accelerate medical research.

Ethical Innovations: Continued advancements in ethical frameworks and governance models will help address the complex ethical issues associated with biobanking.

Personalized Medicine: Biobanks will play a critical role in the continued development of personalized medicine, providing the samples and data needed to tailor treatments to individual patients.

Biobanking Industry: Regional Analysis

North America Market Forecast

North America dominate the Biobanking Market with the highest revenue generating market with share of more than 47%. Leading biobanking companies, robust government support, and advances in personalized medicine foster growth. Extensive R&D activities and a high prevalence of chronic diseases also contribute to the market's expansion.

Europe Market Statistics

Europe’s biobanking market thrives due to its robust regulatory frameworks, strong healthcare systems, and substantial research funding. The region's collaborative research initiatives and cross-border projects enhance biobank operations and data sharing. Supportive policies and funding for innovative research drive the growth and efficiency of biobanks across Europe.

Conclusion

Biobanking is a cornerstone of modern medical research, offering invaluable resources for understanding diseases, developing new treatments, and improving public health. By addressing ethical, legal, and operational challenges, and embracing technological advancements, biobanks can continue to drive scientific discoveries and enhance healthcare outcomes worldwide.

About We Market Research:

WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.

Contact Us:

Mr. Robbin Joseph

Corporate Sales, USA

We Market Research

USA: +1-724-618-3925

Websites: https://wemarketresearch.com/

Email: sales@wemarketresearch.com

[scientificinquirer-blog]

Large-scale proteomics in population-based studies from UK and Iceland.

In an article revealed today in Nature, scientists  from deCODE Genetics, a subsidiary of the pharmaceutical company Amgen, demonstrated how plasma proteomics can contribute to a better understanding of diseases. The study’s focus on the plasma proteome led the team to find associations between various diseases and the levels of specific proteins. “Measuring a great number of proteins in a…

[cro-services]

CRO Services at Clinfinite Solution

Introduction

Clinical research organizations (CROs) play a vital role in the healthcare industry by assisting pharmaceutical companies, biotechnology firms, and medical device manufacturers in conducting clinical trials. At Clinfinite Solution, we provide a full range of CRO services that support the successful development of new drugs, medical devices, and therapies. Our services are designed to ensure that clinical trials are conducted efficiently, accurately, and in compliance with regulatory standards.

Comprehensive Clinical Trial Management

Effective management of clinical trials is crucial for ensuring that research progresses smoothly and achieves its intended goals. At Clinfinite Solution, we offer comprehensive clinical trial management services that oversee every phase of the trial. From planning and design to execution and monitoring, our team of experts ensures that trials are conducted according to protocol, on time, and within budget. Our tailored approach allows us to handle complex clinical trial needs while maintaining high-quality standards.

Patient Recruitment and Retention

Recruiting and retaining patients for clinical trials is often one of the biggest challenges faced by research organizations. At Clinfinite Solution, we employ advanced strategies to recruit the right participants and ensure they remain engaged throughout the trial. Our team uses a mix of traditional and innovative approaches, such as community outreach, digital advertising, and patient education programs, to attract a diverse pool of participants. We also focus on patient retention, providing support and education to participants to ensure they complete the trial successfully.

Regulatory Compliance and Quality Assurance

Ensuring that clinical trials comply with regulatory standards is critical for maintaining the integrity of the study and for obtaining approval from regulatory bodies such as the FDA or EMA. Clinfinite Solution provides regulatory affairs services to ensure that all aspects of your clinical trials meet local and international regulatory requirements. We ensure proper documentation, submission of necessary filings, and adherence to Good Clinical Practice (GCP) guidelines. Our quality assurance team also conducts regular audits and checks to guarantee that all processes are compliant and high-quality.

Data Management and Analysis

Data is the backbone of any clinical trial, and managing it effectively is key to the success of the research. At Clinfinite Solution, we offer advanced data management and analysis services that ensure data is accurate, organized, and readily accessible. Our team uses state-of-the-art technology and software to collect, monitor, and analyze trial data in real time. We provide detailed reports that help stakeholders track the progress of the trial and make data-driven decisions.

Site Management and Monitoring

Effective site management and monitoring are essential for ensuring that clinical trials are conducted in compliance with protocols and regulatory standards. Clinfinite Solution provides site management services to ensure that trial sites are properly equipped and staffed, and that they follow all regulatory guidelines. Our clinical research associates (CRAs) visit sites regularly to monitor trial activities, address issues, and ensure that data is collected and reported accurately.

Medical Writing and Documentation

Accurate and clear documentation is essential in clinical trials. At Clinfinite Solution, we offer expert medical writing services that include the preparation of study protocols, informed consent forms, clinical study reports, and other necessary documentation. Our team of skilled writers ensures that all documents are clear, concise, and compliant with regulatory requirements. This helps ensure that the trial runs smoothly and that regulatory bodies have all the necessary information for review and approval.

Pharmacovigilance Services

CRO is a top priority in clinical trials, and pharmacovigilance plays a key role in monitoring and evaluating the safety of new drugs and therapies. Clinfinite Solution provides pharmacovigilance services that involve tracking adverse events and ensuring that they are reported to the relevant authorities. We maintain strict safety protocols to monitor patients throughout the trial and ensure that any potential risks are addressed promptly.

Conclusion: Comprehensive CRO Services to Support Your Research

At Clinfinite Solution, we offer a wide range of CRO services that support every phase of your clinical trial, from planning and recruitment to data management and regulatory compliance. Our experienced team is dedicated to helping you navigate the complexities of clinical research while ensuring that your trials are conducted efficiently, accurately, and in compliance with all necessary regulations. Whether you are conducting trials for a new drug, medical device, or therapy, Clinfinite Solution is your trusted partner in clinical research. With our expertise, commitment to quality, and tailored approach, we help bring your innovations to market faster and more efficiently.